Research graph
References from Efficacy and Safety of PD ‐1/ PD ‐ L1 Inhibitors Combined With Anti‐Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single‐Arm Meta‐Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Nasopharyngeal Carcinoma
10.1016/s0140-6736(19)30956-0 · 2019 · External reference
Nasopharyngeal Carcinoma: An Evolving Paradigm
10.1038/s41571-021-00524-x · 2021 · External reference
Pattern and Prognosis of Distant Metastases in Nasopharyngeal Carcinoma: A Large‐Population Retrospective Analysis
10.1002/cam4.3301 · 2020 · External reference
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
10.1056/nejmoa1905287 · 2019 · External reference
Camrelizumab Versus Placebo in Combination With Gemcitabine and Cisplatin as First‐Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN‐1st): A Multicentre, Randomised, Double‐Blind, Phase 3 Trial
10.1016/s1470-2045(21)00302-8 · 2021 · External reference
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER‐02 Randomized Clinical Trial
10.1001/jama.2023.20181 · 2023 · External reference
Tislelizumab Plus Chemotherapy as First‐Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: A Multicenter Phase 3 Trial (RATIONALE‐309)
10.1016/j.ccell.2023.04.014 · 2023 · External reference
A Phase II Trial of 5‐Fluorouracil and Cisplatinum in Recurrent or Metastatic Nasopharyngeal Carcinoma
10.1093/oxfordjournals.annonc.a058703 · 1994 · External reference
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment From Present to Future: Where Are we and Where Are we Heading?
10.1007/s11864-023-01101-3 · 2023 · External reference
Protein Tyrosine Kinase Inhibitor Resistance in Malignant Tumors: Molecular Mechanisms and Future Perspective
10.1038/s41392-022-01168-8 · 2022 · External reference
Camrelizumab Plus Rivoceranib Versus Sorafenib as First‐Line Therapy for Unresectable Hepatocellular Carcinoma (CARES‐310): A Randomised, Open‐Label, International Phase 3 Study
10.1016/s0140-6736(23)00961-3 · 2023 · External reference
Research Progress of Small Molecule Anti‐Angiogenic Drugs in Non‐Small Cell Lung Cancer
2021 · External reference
Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma: Clinical Trial Evidence and Experience
10.1177/1756287216663073 · 2016 · External reference
912P Toripalimab in Combination With Anlotinib in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: The Interim Analysis of the Single‐Arm, Phase II TORAL Study
10.1016/j.annonc.2023.09.2057 · 2023 · External reference
Efficacy and Safety of Apatinib or Anlotinib Combined With PD‐1 Inhibitors‐Based Therapy as Subsequent‐Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Real‐World Retrospective Study
10.3389/fonc.2025.1624286 · 2025 · External reference
Anlotinib Reversed Resistance to PD‐1 Inhibitors in Recurrent and Metastatic Head and Neck Cancers: A Real‐World Retrospective Study
10.1007/s00262-024-03784-5 · 2024 · External reference
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open‐Label, Single‐Arm, Phase II Study
10.1200/jco.22.01450 · 2023 · External reference
Camrelizumab Plus Famitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD‐1 Blockade: Data From a Multicohort Phase 2 Study
10.1016/j.eclinm.2023.102043 · 2023 · External reference
Toripalimab Plus Anlotinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single‐Arm Phase 2 Trial (TORAL)
10.1016/j.xcrm.2024.101833 · 2024 · External reference
Camrelizumab Combined With Apatinib in Patients With First‐Line Platinum‐Resistant or PD‐1 Inhibitor‐Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Single‐Arm, Phase 2 Trial
10.1038/s41467-023-40402-x · 2023 · External reference
Unresolved reference
2024 · External reference
Efficacy and Safety of Toripalimab Combined With Apatinib as Second‐Line Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma
2024 · External reference
Efficacy and Safety of PD‐1 Inhibitors Combined With Anti‐Angiogenic Agents in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis
10.1007/s12672-025-04049-y · 2025 · External reference
Cancer Associated Fibroblasts and Metabolic Reprogramming: Unraveling the Intricate Crosstalk in Tumor Evolution
10.1186/s13045-024-01600-2 · 2024 · External reference
The Role of Angiogenesis Inhibitors Associated With Tyrosine Kinase Inhibitors in the First‐Line Treatment for EGFR‐Mutated Advanced Lung Cancer
10.1016/j.critrevonc.2024.104294 · 2024 · External reference
The Application and Research Progress of Anti‐Angiogenesis Therapy in Tumor Immunotherapy
10.3389/fimmu.2023.1198972 · 2023 · External reference
Nivolumab Plus Ipilimumab Versus Sunitinib for First‐Line Treatment of Advanced Renal Cell Carcinoma: Extended 8‐Year Follow‐Up Results of Efficacy and Safety From the Phase III CheckMate 214 Trial
10.1016/j.annonc.2024.07.727 · 2024 · External reference
Patient‐Reported Outcomes With Atezolizumab Plus Bevacizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (IMbrave150): An Open‐Label, Randomised, Phase 3 Trial
10.1016/s1470-2045(21)00151-0 · 2021 · External reference
Updated Efficacy and Safety Data From IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma
10.1016/j.jhep.2021.11.030 · 2022 · External reference
10.1016/j.jtho.2026.103899
10.1016/j.jtho.2026.103899 · External reference
PD‐1 Blockade Plus Tyrosine Kinase Inhibitor Remodels the Tumor Microenvironment in Advanced Renal Cell Carcinoma
10.1038/s41467-026-70978-z · 2026 · External reference
Towards Multidrug Adaptive Therapy
10.1158/0008-5472.can-19-2669 · 2020 · External reference
The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non‐Small Cell Lung Cancer
10.2147/ott.s468932 · 2024 · External reference
Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR2 Inhibitor
10.1007/s00280-023-04534-7 · 2023 · External reference
Anlotinib: A Novel Multi‐Targeting Tyrosine Kinase Inhibitor in Clinical Development
10.1186/s13045-018-0664-7 · 2018 · External reference
